Moderna Rises as CEO Eyes European Market and Flu-Covid Vaccine
Moderna stock jumps 14%, driven by European expansion plans and a new flu-Covid combo vaccine aiming for 2026 approval.
/ 1661 items
#XY↓
ANKTIVA Shows Promise in Lung Cancer Treatment
ImmunityBio's (IBRX) ANKTIVA demonstrates improved immune response and survival in non-small cell lung cancer patients when combined with checkpoint inhibitors.
Travere Therapeutics Stock Plunges on FDA Approval Uncertainty
Travere Therapeutics shares drop 33% in premarket as FDA requests more data for FILSPARI FSGS approval, delaying potential first-ever treatment for rare kidney disease.
BofA Raises Biohaven Price Target to $15 on Pipeline Progress, But Stays Cautious
Bank of America upgrades Biohaven's price target by 50% following positive pipeline updates, but maintains neutral rating citing uncertain 2026 catalysts.
FDA Approves First Treatment for Rare Menkes Disease
ZYCUBO becomes the first FDA-approved treatment for Menkes disease, a rare genetic disorder affecting copper transport in children, offering new hope for patients.
Goldman Sachs Upgrades Arcus Biosciences to Buy on Strong Cancer Drug Data
Goldman Sachs upgraded Arcus Biosciences to Buy, raising its price target to $28 on promising results for its lead cancer drug Casdatifan.